Bio-Rad(BIO) ZACKS·2025-02-13 23:46Core Viewpoint - Bio-Rad Laboratories reported quarterly earnings of $2.90 per share, missing the Zacks Consensus Estimate of $2.93 per share, and down from $3.10 per share a year ago [1][2] Financial Performance - The earnings surprise for the quarter was -1.02%, with the company previously exceeding expectations by 57.03% in the prior quarter [2] - Bio-Rad's revenues for the quarter were $667.5 million, missing the Zacks Consensus Estimate by 1.07%, and down from $681.18 million year-over-year [3] - Over the last four quarters, the company has surpassed consensus EPS estimates three times but has only topped revenue estimates once [2][3] Stock Performance - Bio-Rad shares have declined approximately 4.9% since the beginning of the year, contrasting with the S&P 500's gain of 2.9% [4] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations for outperformance in the near future [7] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.29 on revenues of $625.43 million, and for the current fiscal year, it is $11.57 on revenues of $2.65 billion [8] - The trend of estimate revisions for Bio-Rad has been favorable ahead of the earnings release [7] Industry Context - The Medical - Products industry, to which Bio-Rad belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a positive outlook for stocks in this sector [9]